Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2013
At a glance
- Drugs Figitumumab (Primary) ; Pegvisomant (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 12 Oct 2012 Planned end date changed from 1 Sep 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 10 Sep 2012 Planned end date changed from 1 Aug 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.